The case for rejecting the amyloid cascade hypothesis
- PMID: 26007212
- DOI: 10.1038/nn.4017
The case for rejecting the amyloid cascade hypothesis
Abstract
Alzheimer's disease (AD) is a biologically complex neurodegenerative dementia. Nearly 20 years ago, with the combination of observations from biochemistry, neuropathology and genetics, a compelling hypothesis known as the amyloid cascade hypothesis was formulated. The core of this hypothesis is that it is pathological accumulations of amyloid-β, a peptide fragment of a membrane protein called amyloid precursor protein, that act as the root cause of AD and initiate its pathogenesis. Yet, with the passage of time, growing amounts of data have accumulated that are inconsistent with the basically linear structure of this hypothesis. And while there is fear in the field over the consequences of rejecting it outright, clinging to an inaccurate disease model is the option we should fear most. This Perspective explores the proposition that we are over-reliant on amyloid to define and diagnose AD and that the time has come to face our fears and reject the amyloid cascade hypothesis.
Similar articles
-
Alzheimer's disease.Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Subcell Biochem. 2012. PMID: 23225010 Review.
-
On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis.Ageing Res Rev. 2014 Jan;13:10-2. doi: 10.1016/j.arr.2013.10.001. Epub 2013 Nov 16. Ageing Res Rev. 2014. PMID: 24252390 Review.
-
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.Neuropeptides. 2015 Aug;52:1-18. doi: 10.1016/j.npep.2015.06.008. Epub 2015 Jul 2. Neuropeptides. 2015. PMID: 26149638 Review.
-
Perspectives on the amyloid-beta cascade hypothesis.J Alzheimers Dis. 2004 Apr;6(2):137-45. doi: 10.3233/jad-2004-6205. J Alzheimers Dis. 2004. PMID: 15096697 Review.
-
Alzheimer's disease and the amyloid cascade hypothesis: ten years on.Curr Opin Pharmacol. 2002 Feb;2(1):87-92. doi: 10.1016/s1471-4892(01)00126-6. Curr Opin Pharmacol. 2002. PMID: 11786314 Review.
Cited by
-
Battling Alzheimer's Disease: Targeting SUMOylation-Mediated Pathways.Neurochem Res. 2016 Mar;41(3):568-78. doi: 10.1007/s11064-015-1681-3. Epub 2015 Jul 31. Neurochem Res. 2016. PMID: 26227998 Review.
-
Brain cells derived from Alzheimer's disease patients have multiple specific innate abnormalities in energy metabolism.Mol Psychiatry. 2021 Oct;26(10):5702-5714. doi: 10.1038/s41380-021-01068-3. Epub 2021 Apr 16. Mol Psychiatry. 2021. PMID: 33863993 Free PMC article.
-
Lost in translation: Inconvenient truths on the utility of mouse models in Alzheimer's disease research.Elife. 2024 Sep 27;13:e90633. doi: 10.7554/eLife.90633. Elife. 2024. PMID: 39329365 Free PMC article. Review.
-
Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's Disease.Molecules. 2016 Apr 8;21(4):466. doi: 10.3390/molecules21040466. Molecules. 2016. PMID: 27070562 Free PMC article. Review.
-
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.EC Pharmacol Toxicol. 2019 Jul;7(7):547-558. Epub 2019 Jun 21. EC Pharmacol Toxicol. 2019. PMID: 31565701 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases